VITRO DIAGNOSTICS, INC. (OTCMKTS:VODG) Files An 8-K Termination of a Material Definitive Agreement

VITRO DIAGNOSTICS, INC. (OTCMKTS:VODG) Files An 8-K Termination of a Material Definitive Agreement
ITEM 1.02

Story continues below


On October 12, 2017, the Company and DaVinci Centre for Wellness and Alternative Therapies, Ltd (“DaVinci”) mutually agreed in writing to terminate and unwind the previously executed revised Stem Cell Lab Development Agreement (“Revised Agreement”) to which DaVinci was to provide the clinical facilities and staff support necessary for the Company to begin offering stem cell therapies in the Cayman Islands. The Revised Agreement was to become effective upon the funding of a $1.5 million financing. That financing did not occur. Details of the Revised Agreement were previously reported in the Company’s Current Report on Form 8-K dated July 6, 2017 and filed with the Securities and Exchange Commission on July 11, 2017.


Vitro Diagnostics, Inc., doing business as Vitro Biopharma, is engaged in the development, manufacturing and distribution of stem cell products and related tools for use in research, drug discovery and clinical trials. The Company’s clinical products include clinical grade MSC-Gro for mesenchymal stem cell (MSC) expansion prior to transplantation; an equine MSC cell line with application to treatment of skeletal muscular conditions, such as tendonitis, ligament injury, osteoarthritis and accelerated bone fracture healing, and others; testing and therapies related to endogenous stem cell activation; diagnostic testing of stem cell activation and determination of stem cell functional status, and cell-based assays for discovery of stem cell activation agents and new drugs for the treatment of osteoporosis. The Company offers cancer-associated fibroblasts (CAFs), which are used in the discovery of a new type of CAFs present in pancreatic cancer tumors, called pancreatic stellate cells.

An ad to help with our costs